Effect of oral posaconazole on the pharmacokinetics of cyclosporins and tacrolimus

Pharmacotherapy

Volumn 27, Issue 6, 2007, Pages 825-834

  Sansone Parsons, Angela ^a,d   Krishna, Gopal ^a   Martinho, Monika ^a   Kantesaria, Bhavna ^a   Gelone, Steven ^b   Mant, Tim G ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b TEMPLE UNIVERSITY   (United States)

^c GUY S HOSPITAL   (United Kingdom)

^d NONE   (United States)

Author keywords

Cyclosporine; Drug interaction; Posaconazole; Tacrolimus

Indexed keywords

CYCLOSPORIN; POSACONAZOLE; TACROLIMUS;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BACKACHE; BLOOD SAMPLING; CASE REPORT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG MONITORING; DYSURIA; EVALUATION; FEMALE; FLANK PAIN; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTRITIS; HEADACHE; HEART TRANSPLANTATION; HEMATURIA; HERPES ULCER; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; LOOSE FECES; MACULOPAPULAR RASH; MALE; MONOTHERAPY; NAUSEA; NONHERPETIC COLD SORE; NORMAL HUMAN; NOSE CONGESTION; OPEN STUDY; PAIN; PARESTHESIA; SIDE EFFECT; SINGLE DRUG DOSE; SKIN ULCER; TASTE DISORDER; TASTE PERVERSION; THIRST; URINARY TRACT INFECTION;

ADULT; ANTIBIOTICS, ANTIFUNGAL; AREA UNDER CURVE; CROSS-OVER STUDIES; CYCLOSPORINE; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; TACROLIMUS; TRIAZOLES;

EID: 34249793693     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.6.825     Document Type: Article

References (49)

1. Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis 1993;16:677-88.
2. Fukuda T, Boeckh M, Guthrie KA, et al. Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant 2004;10:494-503.
3. Combalbert J, Fabre I, Fabre G, et al. Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 1989;17:197-207.
4. Vincent SH, Karanam BV, Painter SK, Chiu SH. In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism. Arch Biochem Biophys 1992;294:454-60.
5. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000;38:111-80.
6. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993;268:6077-80.
7. Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW. Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother 2002;46:160-5.
8. Romero AJ, Pogamp PL, Nilsson LG, Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2002;71:226-34.
9. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995;58:15-19.
10. Back DJ, Tjia JF. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 1991;32:624-6.
11. Canafax DM, Graves NM, Hilligoss DM, Carleton BC, Gardner MJ, Matas AJ. Interaction between cyclosporine and fluconazole in renal allograft recipients. Transplantation 1991;51:1014-18.
12. Trenk D, Brett W, Jahnchen E, Birnbaum D. Time course of cyclosporin/itraconazole interaction. Lancet 1987;2:1335-6.
13. Florea NR, Capitano B, Nightingale CH, Hull D, Leitz GJ, Nicolau DP. Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients. Transplant Proc 2003;35:2873-7.
14. Sud K, Singh B, Krishna VS, et al. Unpredictable cyclosporin - fluconazole interaction in renal transplant recipients. Nephrol Dial Transplant 1999;14:1698-703.
15. Foradori A, Mezzano S, Videla C, Pefaur J, Elberg A. Modification of the pharmacokinetics of cyclosporine A and metabolites by the concomitant use of Neoral and diltiazem or ketoconazol in stable adult kidney transplants. Transplant Proc 1998;30:1685-7.
16. Osowski CL, Dix SP, Lin LS, Mullins RE, Geller RB, Wingard JR. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation 1996;61:1268-72.
17. Koselj M, Bren A, Kandus A, Kovac D. Drug interactions between cyclosporine and rifampicin, erythromycin, and azoles in kidney recipients with opportunistic infections. Transplant Proc 1994;26:2823-4.
18. Wood N, Tan K, Allan R, Fielding A, Nichols DJ. Effect of voriconazole on the pharmacokinetics of tacrolimus. Presented at 41st interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, December 16-19, 2001.
19. Floren LC, Bekersky I, Benet LZ, et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997;62:41-9.
20. Billaud EM, Guillemain R, Tacco F, Chevalier P. Evidence for a pharmacokinetic interaction between itraconazole and tacrolimus in organ transplant patients. Br J Clin Pharmacol 1998;46:271-2.
21. Vasquez EM, Pollak R, Benedetti E. Clotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patients. Clin Transplant 2001;15:95-9.
22. Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents: drug interactions of clinical significance. Drug Saf 1998;18:83-97.
23. Van Gelder T. Drug interactions with tacrolimus. Drug Saf 2002;25:707-12.
24. Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int 2000;13:313-26.
25. Singh N, Bonham A, Fukui M. Immunosuppressive-associated leukoencephalopathy in organ transplant recipients. Transplantation 2000;4:467-72.
26. Astellas Pharma US, Inc. Prograf tacrolimus capsules, tacrolimus injection package insert. Deerfield, IL; July 2005.
27. Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003;47: 3149-54.
28. Pfaller MA, Messer SA, Hollis RJ, Jones RN. In vitro activities of posaconazole (SCH 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother 2001;45:2862-4.
29. Pfaller MA, Messer SA, Boyken L, et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004;48:201-5.
30. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998;36:2950-6.
31. Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003;41:3623-6.
32. Anstead GM, Martinez M, Graybill JR. Control of a Candida glabrata prosthetic endovascular infection with posaconazole. Med Mycol 2006;44:273-7.
33. Tobon A, Correa AL, Arango M, de Bedout C, Restrepo A. Posaconazole therapy for severe abdominal candidiasis: a case report. Revi Iberoam Micol 2004;21:78-80.
34. Walsh T, Patterson T, Langston A, et al. Posaconazole for treatment of invasive aspergillosis in patients who are refractory to or intolerant of conventional therapy: an externally controlled blinded trial [abstract]. Blood 2003;102:195-6.
35. Krieter P, Flannery B, Musick T, Gohdes M, Martinho M, Courtney R. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004;48:3543-51.
36. Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004;21:645-53.
37. Schering Corporation. Data on file. Lafayette, NJ; 2001.
38. Gibaldi M, Perrier D. Pharmacokinetics, 2nd ed. New York: Marcel Dekker, 1982:409-17.
39. Courtney R, Radwanski E, Lim J, Laughlin M. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother 2004;48:804-8.
40. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2003;57:218-22.
41. Courtney R, Sansone A, Statkavich P, Martinho M, Laughlin M. Assessment of the pharmacokinetic (pk), and pharmacodynamic (pd) interaction potential between posaconazole and glipizide in healthy volunteers [poster]. Presented at the annual meeting of the European society of clinical pharmacology and therapeutics, Washington, D.C., April 2-5, 2003.
42. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995;29:404-30.
43. National Cancer Institute. Common toxicity criteria, version 2.0. Available from http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf. Accessed April 4, 2007.
44. Gubbins PO, Krishna G, Sansone-Parsons A, et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother 2006;50:1993-9.
45. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006;50:658-66.
46. Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993;24:472-95.
47. Schering Corporation. Noxafil (posaconazole) oral suspension package insert. Kenilworth, NJ; October 2006.
48. Langston A, Ullmann AJ, Comely OA, et al. Pharmacokinetics (PK) and safety of posaconazole (POS) as prophylaxis for invasive fungal infection (IFI) in high-risk patients (Pts). Presented at the 46th interscience conference on antimicrobial agents and chemotherapy, San Francisco, CA, September 27-30, 2006.
49. Venkataramanan R, Zang S, Gayowski T, Singh N. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agents Chemother 2002;46:3091-3.